[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Biofilms Treatment Market by Products (Debridement Equipment, Gauze, Dressing, Gel, Ointment), Wound Type (Traumatic, Surgical, Open, Diabetic Foot, Venous Leg Ulcer & Burns), End User (Hospital, ASCs, Wound Care Centers, Homecare)-Global Forecast to 2025

May 2020 | 151 pages | ID: BE330E2956A6EN
MarketsandMarkets

US$ 4,950.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
“Rising incidence of burn injuries is driving the growth of the biofilms treatment market”

The biofilms treatment market is projected to reach USD 2.4 billion by 2025 from USD 1.6 billion in 2020, at a CAGR of 7.9%. The growth of this market is majorly driven by the rising prevalence of chronic, surgical, and traumatic wounds and the increasing incidence of burn injuries. However, the high cost and low adoption rate of advanced wound care products are expected to limit the growth of this market to a certain extent.

“Gauzes and dressings segment accounted for the largest share of the biofilms treatment market in 2019”

Based on product, the biofilms treatment market is segmented into debridement equipment; gauzes and dressings; gels, ointments, and sprays; wipes, pads, and lavage solutions; and grafts and matrices. The gauzes and dressings segment accounted for the largest market share in 2019. This can be attributed to the ability of antimicrobial products to remove, prevent, and manage biofilms.

“Traumatic and surgical wounds segment will continue to dominate the biofilms treatment market during the forecast period”

Based on wound type, the biofilms treatment market is segmented into surgical and traumatic wounds, diabetic foot ulcers, pressure ulcers, venous leg ulcers, and burns and other open wounds. The surgical and traumatic wounds segment accounted for the largest market share in 2019. The large share of this segment can be attributed to the growing prevalence of diabetes and the increasing number of surgical procedures performed.

“North America dominates the global biofilms treatment market”

In 2019, North America accounted for the largest share of the biofilms treatment market, and this trend is expected to continue during the forecast period. The large share of this market can be attributed to the increasing incidence of chronic wounds, rising healthcare expenditure, the introduction of novel and specialty biofilm management products, and the presence of major market players in this region.

The primary interviews conducted for this report can be categorized as follows:
  • By Company Type: Tier 1 - 36%, Tier 2 - 45%, and Tier 3 - 19%
  • By Designation: C-level - 33%, D-level - 40%, and Others - 27%
  • By Region: North America - 39%, Europe - 30%, Asia Pacific - 20%, Latin America- 8%, and the Middle East and Africa- 3%
List of Companies Profiled in the Report
  • Smith & Nephew (UK)
  • MiMedx Group Inc. (US)
  • ConvaTec Group plc (UK)
  • Coloplast A/S (Denmark)
  • M?lnlycke Healthcare AB (Sweden)
  • Organogenesis Holdings Inc. (US)
  • Integra LifeSciences Holdings Corporation (US)
  • B. Braun Melsungen AG (Germany)
  • PAUL HARTMANN AG (Germany)
  • Medline Industries Inc. (US)
  • Acelity (US)
  • Misonix (US)
  • Zimmer Biomet Holdings Inc. (US)
  • Kerecis (Iceland)
  • Welcare Industries S.p.A (Italy)
  • Medaxis AG (Switzerland)
  • PulseCare Medical (US)
  • Arobella Medical, LLC (UK)
  • RLS Global AB (Sweden)
  • Mil Laboratories Pvt. Ltd. (India)
Research Coverage:

This report provides a detailed picture of the global biofilms treatment market. It aims at estimating the size and future growth potential of the market across different segments, such as product, end user, wound type, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall biofilms treatment market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the pulse of the market and provide them with information on the key market drivers, restraints, and opportunities.
1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
  1.2.1 MARKET SCOPE
  1.2.2 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATIONS
1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
  2.2.1 SECONDARY DATA
    2.2.1.1 Key data from secondary sources
  2.2.2 PRIMARY DATA
2.3 MARKET SIZE ESTIMATION
  2.3.1 BOTTOM-UP APPROACH
  2.3.2 TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 BIOFILMS TREATMENT MARKET OVERVIEW
4.2 BIOFILMS TREATMENT MARKET, BY PRODUCT, 2020 VS. 2025 (USD MILLION)
4.3 BIOFILMS TREATMENT MARKET SHARE, BY END USER, 2020 VS. 2025
4.4 BIOFILMS TREATMENT MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

5.1 INTRODUCTION
5.2 MARKET DYNAMICS
  5.2.1 DRIVERS
    5.2.1.1 Growing prevalence of chronic, surgical, and traumatic wounds
      5.2.1.1.1 High incidence of obesity
      5.2.1.1.2 Growing geriatric population
      5.2.1.1.3 Increasing prevalence of diabetes
      5.2.1.1.4 Increase in the number of surgical wounds and SSIs
      5.2.1.1.5 Increasing number of traumatic wounds
    5.2.1.2 Increasing incidence of burn injuries
  5.2.2 OPPORTUNITIES
    5.2.2.1 Growth potential in emerging economies
  5.2.3 CHALLENGES
    5.2.3.1 High cost and low adoption rate of advanced wound care products

6 BIOFILMS TREATMENT MARKET, BY PRODUCT

6.1 INTRODUCTION
6.2 DEBRIDEMENT EQUIPMENT
  6.2.1 DEVELOPMENT OF NOVEL TECHNOLOGIES TO SUPPORT MARKET GROWTH
6.3 GAUZES AND DRESSINGS
  6.3.1 GAUZES AND DRESSINGS ARE DESIGNED TO PREVENT THE OCCURRENCE OF INFECTIONS AFTER DEBRIDEMENT PROCEDURES
6.4 GRAFTS AND MATRICES
  6.4.1 GRAFTS AND MATRICES PROMOTE HEALING AND WOUND CLOSURE
6.5 WIPES, PADS, AND LAVAGE SOLUTIONS
  6.5.1 LAVAGE SOLUTIONS ARE USED FOR CLEANING WOUNDS DURING HYDRO SURGICAL AND MECHANICAL DEBRIDEMENT PROCEDURES
6.6 GELS, OINTMENTS, AND SPRAYS
  6.6.1 THESE PRODUCTS ARE USED TO TREAT BURNS, DIABETIC FOOT ULCERS, AND SURGICAL & TRAUMATIC WOUNDS

7 BIOFILMS TREATMENT MARKET, BY WOUND TYPE

7.1 INTRODUCTION
7.2 SURGICAL AND TRAUMATIC WOUNDS
  7.2.1 GROWING VOLUME OF SURGICAL PROCEDURES PERFORMED TO SUPPORT MARKET GROWTH
7.3 DIABETIC FOOT ULCERS
  7.3.1 RISING PREVALENCE OF DIABETES IS A KEY FACTOR DRIVING THE GROWTH OF THIS SEGMENT
7.4 PRESSURE ULCERS
  7.4.1 GERIATRIC POPULATION IS MORE SUSCEPTIBLE TO DEVELOPING PRESSURE ULCERS
7.5 VENOUS LEG ULCERS
  7.5.1 INCREASING PREVALENCE OF OBESITY TO SUPPORT MARKET GROWTH
7.6 BURNS & OTHER OPEN WOUNDS
  7.6.1 INCIDENCE OF BURN INJURIES IS HIGH IN EMERGING COUNTRIES

8 BIOFILMS TREATMENT MARKET, BY END USER

8.1 INTRODUCTION
8.2 HOSPITALS, ASCS, AND WOUND CARE CENTERS
  8.2.1 RISING INCIDENCE OF HOSPITAL-ACQUIRED PRESSURE ULCERS AND INFECTIONS TO SUPPORT MARKET GROWTH
8.3 HOME CARE SETTINGS
  8.3.1 RISING PREFERENCE FOR HOME HEALTHCARE IS CONTRIBUTING TO
THE GROWTH OF THIS MARKET
8.4 OTHER END USERS

9 BIOFILMS TREATMENT MARKET, BY REGION

9.1 INTRODUCTION
9.2 NORTH AMERICA
  9.2.1 US
    9.2.1.1 Rising prevalence of diabetes and favorable reimbursement policies in the country to boost the market growth
  9.2.2 CANADA
    9.2.2.1 Increasing government support to boost market growth
9.3 EUROPE
  9.3.1 UK
    9.3.1.1 Increase in R&D activities to propel market growth in the UK
  9.3.2 GERMANY
    9.3.2.1 Increasing incidence of diabetes will boost the market growth in Germany
  9.3.3 RUSSIA
    9.3.3.1 Government focus on increasing diabetes awareness will favor market growth in Russia
  9.3.4 FRANCE
    9.3.4.1 Rising geriatric population to drive the demand for advanced wound care products in the country
  9.3.5 ITALY
    9.3.5.1 Unfavorable reimbursement scenario for advanced wound care will hinder market growth in Italy
  9.3.6 SPAIN
    9.3.6.1 Rising geriatric population in the country to support market growth
  9.3.7 REST OF EUROPE
9.4 ASIA PACIFIC
  9.4.1 CHINA
    9.4.1.1 Increasing incidence of DFUs to support market growth in China
  9.4.2 JAPAN
    9.4.2.1 Favorable regulations in Japan have boosted product launch and commercialization activity
  9.4.3 INDIA
    9.4.3.1 High rate of SSIs and growing investments indicate strong opportunities for market growth
  9.4.4 AUSTRALIA
    9.4.4.1 Increasing initiatives to spread awareness on effective wound care to support market growth
  9.4.5 REST OF ASIA PACIFIC
9.5 LATIN AMERICA
  9.5.1 BRAZIL
    9.5.1.1 Brazil is the largest market for healthcare in the Latin American region
  9.5.2 MEXICO
    9.5.2.1 Diabetes is the second-highest cause of mortality in Mexico
  9.5.3 REST OF LATIN AMERICA
9.6 MIDDLE EAST & AFRICA
  9.6.1 GROWING PREVALENCE OF DIABETES TO SUPPORT MARKET GROWTH

10 COMPETITIVE LANDSCAPE

10.1 INTRODUCTION
10.2 MARKET SHARE ANALYSIS, 2019
  10.2.1 BIOFILMS TREATMENT MARKET, BY KEY PLAYER
  10.2.2 BIOFILMS TREATMENT MARKET FOR HOSPITALS
  10.2.3 BIOFILMS TREATMENT MARKET FOR HOME CARE SETTINGS
10.3 COMPETITIVE LEADERSHIP MAPPING (OVERALL MARKET)
10.4 VENDOR INCLUSION CRITERIA
10.5 VENDOR DIVE
  10.5.1 VISIONARY LEADERS
  10.5.2 INNOVATORS
  10.5.3 DYNAMIC DIFFERENTIATORS
  10.5.4 EMERGING COMPANIES
10.6 COMPETITIVE SCENARIO
  10.6.1 PRODUCT LAUNCHES & APPROVALS
  10.6.2 ACQUISITIONS
  10.6.3 COLLABORATIONS & PARTNERSHIPS

11 COMPANY PROFILES

(Business overview, Products offered, Recent developments, SWOT analysis, MNM view)*
11.1 SMITH AND NEPHEW PLC
11.2 MIMEDX GROUP
11.3 CONVATEC GROUP PLC
11.4 INTEGRA LIFESCIENCES HOLDINGS CORPORATION
11.5 PAUL HARTMANN AG
11.6 M?LNLYCKE HEALTH CARE AB
11.7 COLOPLAST A/S
11.8 B. BRAUN MELSUNGEN AG
11.9 ORGANOGENESIS HOLDINGS INC.
11.10 MISONIX
11.11 ACELITY (A PART OF 3M)
11.12 ZIMMER BIOMET HOLDINGS INC.
11.13 KERECIS
11.14 MEDLINE INDUSTRIES, INC.
11.15 WELCARE INDUSTRIES S.P.A
11.16 MEDAXIS AG
11.17 PULSECARE MEDICAL
11.18 AROBELLA MEDICAL, LLC
11.19 ADVANCIS MEDICAL
11.20 RLS GLOBAL AB
11.21 MIL LABORATORIES PVT. LTD.
*Business overview, Products offered, Recent developments, SWOT analysis, MNM view might not be captured in case of unlisted companies.

12 APPENDIX

12.1 DISCUSSION GUIDE
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 AVAILABLE CUSTOMIZATIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS

LIST OF TABLES

TABLE 1 INCLUSIONS & EXCLUSIONS
TABLE 2 AVERAGE SELLING PRICE OF VARIOUS PRODUCTS USED IN THE BIOFILMS TREATMENT MARKET (USD)
TABLE 3 GLOBAL BIOFILMS TREATMENT MARKET BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 4 DEBRIDEMENT EQUIPMENT MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 5 NORTH AMERICA: DEBRIDEMENT EQUIPMENT MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 6 EUROPE: DEBRIDEMENT EQUIPMENT MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 7 APAC: DEBRIDEMENT EQUIPMENT MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 8 GAUZES AND DRESSINGS MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 9 NORTH AMERICA: GAUZES AND DRESSINGS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 10 EUROPE: GAUZES AND DRESSINGS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 11 APAC: GAUZES AND DRESSINGS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 12 GRAFTS AND MATRICES MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 13 NORTH AMERICA: GRAFTS AND MATRICES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 14 EUROPE: GRAFTS AND MATRICES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 15 APAC: GRAFTS AND MATRICES MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 16 WIPES, PADS, AND LAVAGE SOLUTIONS MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 17 NORTH AMERICA: WIPES, PADS, AND LAVAGE SOLUTIONS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 18 EUROPE: WIPES, PADS, AND LAVAGE SOLUTIONS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 19 APAC: WIPES, PADS, AND LAVAGE SOLUTIONS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 20 GELS, OINTMENTS, AND SPRAYS MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 21 NORTH AMERICA: GELS, OINTMENTS, AND SPRAYS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 22 EUROPE: GELS, OINTMENTS, AND SPRAYS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 23 APAC: GELS, OINTMENTS, AND SPRAYS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 24 BIOFILMS TREATMENT MARKET, BY WOUND TYPE, 2018–2025 (USD MILLION)
TABLE 25 BIOFILMS TREATMENT MARKET FOR SURGICAL AND TRAUMATIC WOUNDS, BY REGION, 2018–2025 (USD MILLION)
TABLE 26 BIOFILMS TREATMENT MARKET FOR DIABETIC FOOT ULCERS, BY REGION, 2018–2025 (USD MILLION)
TABLE 27 BIOFILMS TREATMENT MARKET FOR PRESSURE ULCERS, BY REGION, 2018–2025 (USD MILLION)
TABLE 28 BIOFILMS TREATMENT MARKET FOR VENOUS LEG ULCERS, BY REGION, 2018–2025 (USD MILLION)
TABLE 29 HOSPITAL ADMISSIONS FOR THE TREATMENT OF BURN INJURIES, 2015
TABLE 30 BIOFILMS TREATMENT MARKET FOR BURNS AND OTHER OPEN WOUNDS, BY REGION, 2018–2025 (USD MILLION)
TABLE 31 BIOFILMS TREATMENT MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 32 BIOFILMS TREATMENT MARKET FOR HOSPITALS, ASCS, AND WOUND CARE CENTERS, BY REGION, 2018–2025 (USD MILLION)
TABLE 33 BIOFILMS TREATMENT MARKET FOR HOME CARE SETTINGS, BY REGION, 2018–2025 (USD MILLION)
TABLE 34 BIOFILMS TREATMENT MARKET FOR OTHER END USERS, BY REGION, 2018–2025 (USD MILLION)
TABLE 35 BIOFILMS TREATMENT MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 36 NUMBER OF BIOFILM WOUND CASES, BY REGION, 2018–2025 (MILLION)
TABLE 37 NORTH AMERICA: BIOFILMS TREATMENT MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 38 NORTH AMERICA: BIOFILMS TREATMENT MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 39 NORTH AMERICA: BIOFILMS TREATMENT MARKET, BY WOUND TYPE, 2018–2025 (USD MILLION)
TABLE 40 NORTH AMERICA: BIOFILMS TREATMENT MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 41 US: BIOFILMS TREATMENT MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 42 US: BIOFILMS TREATMENT MARKET, BY WOUND TYPE, 2018–2025 (USD MILLION)
TABLE 43 US: BIOFILMS TREATMENT MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 44 CANADA: INCIDENCE OF DIABETES, 2016 VS. 2026
TABLE 45 CANADA: BIOFILMS TREATMENT MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 46 CANADA: BIOFILMS TREATMENT MARKET, BY WOUND TYPE, 2018–2025 (USD MILLION)
TABLE 47 CANADA: BIOFILMS TREATMENT MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 48 EUROPE: PREVALENCE OF DIABETES, 2015 VS. 2040
TABLE 49 EUROPE: BIOFILMS TREATMENT MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 50 EUROPE: BIOFILMS TREATMENT MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 51 EUROPE: BIOFILMS TREATMENT MARKET, BY WOUND TYPE, 2018–2025 (USD MILLION)
TABLE 52 EUROPE: BIOFILMS TREATMENT MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 53 UK: BIOFILMS TREATMENT MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 54 UK: BIOFILMS TREATMENT MARKET, BY WOUND TYPE, 2018–2025 (USD MILLION)
TABLE 55 UK: BIOFILMS TREATMENT MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 56 GERMANY: BIOFILMS TREATMENT MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 57 GERMANY: BIOFILMS TREATMENT MARKET, BY WOUND TYPE, 2018–2025 (USD MILLION)
TABLE 58 GERMANY: BIOFILMS TREATMENT MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 59 RUSSIA: BIOFILMS TREATMENT MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 60 RUSSIA: BIOFILMS TREATMENT MARKET, BY WOUND TYPE, 2018–2025 (USD MILLION)
TABLE 61 RUSSIA: BIOFILMS TREATMENT MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 62 FRANCE: BIOFILMS TREATMENT MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 63 FRANCE: BIOFILMS TREATMENT MARKET, BY WOUND TYPE, 2018–2025 (USD MILLION)
TABLE 64 FRANCE: BIOFILMS TREATMENT MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 65 ITALY: BIOFILMS TREATMENT MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 66 ITALY: BIOFILMS TREATMENT MARKET, BY WOUND TYPE, 2018–2025 (USD MILLION)
TABLE 67 ITALY: BIOFILMS TREATMENT MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 68 SPAIN: BIOFILMS TREATMENT MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 69 SPAIN: BIOFILMS TREATMENT MARKET, BY WOUND TYPE, 2018–2025 (USD MILLION)
TABLE 70 SPAIN: BIOFILMS TREATMENT MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 71 ROE: BIOFILMS TREATMENT MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 72 ROE: BIOFILMS TREATMENT MARKET, BY WOUND TYPE, 2018–2025 (USD MILLION)
TABLE 73 ROE: BIOFILMS TREATMENT MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 74 APAC: BIOFILMS TREATMENT MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 75 APAC: BIOFILMS TREATMENT MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 76 APAC: BIOFILMS TREATMENT MARKET, BY WOUND TYPE, 2018–2025 (USD MILLION)
TABLE 77 APAC: BIOFILMS TREATMENT MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 78 CHINA: BIOFILMS TREATMENT MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 79 CHINA: BIOFILMS TREATMENT MARKET, BY WOUND TYPE, 2018–2025 (USD MILLION)
TABLE 80 CHINA: BIOFILMS TREATMENT MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 81 JAPAN: BIOFILMS TREATMENT MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 82 JAPAN: BIOFILMS TREATMENT MARKET, BY WOUND TYPE, 2018–2025 (USD MILLION)
TABLE 83 JAPAN: BIOFILMS TREATMENT MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 84 INDIA: BIOFILMS TREATMENT MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 85 INDIA: BIOFILMS TREATMENT MARKET, BY WOUND TYPE, 2018–2025 (USD MILLION)
TABLE 86 INDIA: BIOFILMS TREATMENT MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 87 AUSTRALIA: BIOFILMS TREATMENT MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 88 AUSTRALIA: BIOFILMS TREATMENT MARKET, BY WOUND TYPE, 2018–2025 (USD MILLION)
TABLE 89 AUSTRALIA: BIOFILMS TREATMENT MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 90 TOTAL DIABETES-RELATED HEALTH EXPENDITURE, 2019 VS. 2030 (USD MILLION)
TABLE 91 ROAPAC: BIOFILMS TREATMENT MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 92 ROAPAC: BIOFILMS TREATMENT MARKET, BY WOUND TYPE, 2018–2025 (USD MILLION)
TABLE 93 ROAPAC: BIOFILMS TREATMENT MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 94 LATAM: BIOFILMS TREATMENT MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 95 LATAM: BIOFILMS TREATMENT MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 96 LATAM: BIOFILMS TREATMENT MARKET, BY WOUND TYPE, 2018–2025 (USD MILLION)
TABLE 97 LATAM: BIOFILMS TREATMENT MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 98 BRAZIL: BIOFILMS TREATMENT MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 99 BRAZIL: BIOFILMS TREATMENT MARKET, BY WOUND TYPE, 2018–2025 (USD MILLION)
TABLE 100 BRAZIL: BIOFILMS TREATMENT MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 101 MEXICO: BIOFILMS TREATMENT MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 102 MEXICO: BIOFILMS TREATMENT MARKET, BY WOUND TYPE, 2018–2025 (USD MILLION)
TABLE 103 MEXICO: BIOFILMS TREATMENT MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 104 ROLATAM: BIOFILMS TREATMENT MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 105 ROLATAM: BIOFILMS TREATMENT MARKET, BY WOUND TYPE, 2018–2025 (USD MILLION)
TABLE 106 ROLATAM: BIOFILMS TREATMENT MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 107 MIDDLE EAST & AFRICA: BIOFILMS TREATMENT MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 108 MIDDLE EAST & AFRICA: BIOFILMS TREATMENT MARKET, BY WOUND TYPE, 2018–2025 (USD MILLION)
TABLE 109 MIDDLE EAST & AFRICA: BIOFILMS TREATMENT MARKET, BY END USER, 2018–2025 (USD MILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH DESIGN
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 3 BIOFILMS TREATMENT MARKET: BOTTOM-UP APPROACH
FIGURE 4 BIOFILMS TREATMENT MARKET: TOP-DOWN APPROACH
FIGURE 5 DATA TRIANGULATION METHODOLOGY
FIGURE 6 BIOFILMS TREATMENT MARKET, BY PRODUCT, 2020 VS. 2025 (USD MILLION)
FIGURE 7 BIOFILMS TREATMENT MARKET, BY WOUND TYPE, 2020 VS. 2025 (USD MILLION)
FIGURE 8 BIOFILMS TREATMENT MARKET, BY END USER, 2020 VS. 2025 (USD MILLION)
FIGURE 9 BIOFILMS TREATMENT MARKET, BY REGION, 2020 VS. 2025 (USD MILLION)
FIGURE 10 INCREASING PREVALENCE OF CHRONIC, TRAUMATIC, AND SURGICAL WOUNDS WILL DRIVE MARKET GROWTH DURING THE FORECAST PERIOD
FIGURE 11 GAUZES AND DRESSINGS WILL CONTINUE TO DOMINATE THE BIOFILMS TREATMENT MARKET DURING THE FORECAST PERIOD
FIGURE 12 HOSPITALS, ASCS, AND WOUND CARE CENTERS TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2020
FIGURE 13 ASIA PACIFIC TO WITNESS THE HIGHEST GROWTH RATE IN THE FORECAST PERIOD
FIGURE 14 BIOFILMS TREATMENT MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES
FIGURE 15 INCIDENCE OF DIABETES, BY REGION, 2015 VS. 2040 (MILLION CASES)
FIGURE 16 NORTH AMERICA: BIOFILMS TREATMENT MARKET SNAPSHOT
FIGURE 17 ASIA PACIFIC: BIOFILMS TREATMENT MARKET SNAPSHOT
FIGURE 18 KEY DEVELOPMENTS BY LEADING PLAYERS IN THE BIOFILMS TREATMENT MARKET
FIGURE 19 BIOFILMS TREATMENT MARKET SHARE, BY KEY PLAYER, 2019
FIGURE 20 BIOFILMS TREATMENT MARKET SHARE FOR HOSPITALS, BY KEY PLAYER, 2019
FIGURE 21 BIOFILMS TREATMENT MARKET SHARE FOR HOME CARE SETTINGS, BY KEY PLAYER, 2019
FIGURE 22 BIOFILMS TREATMENT MARKET (GLOBAL) COMPETITIVE LEADERSHIP
MAPPING, 2019
FIGURE 23 SMITH AND NEPHEW PLC: COMPANY SNAPSHOT (2019)
FIGURE 24 CONVATEC GROUP PLC: COMPANY SNAPSHOT (2019)
FIGURE 25 INTEGRA LIFESCIENCES HOLDINGS CORPORATION: COMPANY SNAPSHOT (2019)
FIGURE 26 PAUL HARTMANN AG: COMPANY SNAPSHOT (2019)
FIGURE 27 M?LNLYCKE HEALTH CARE AB: COMPANY SNAPSHOT (2018)
FIGURE 28 COLOPLAST A/S: COMPANY SNAPSHOT (2019)
FIGURE 29 B. BRAUN MELSUNGEN AG: COMPANY SNAPSHOT (2019)
FIGURE 30 ORGANOGENESIS HOLDINGS INC.: COMPANY SNAPSHOT (2018)
FIGURE 31 MISONIX: COMPANY SNAPSHOT (2019)
FIGURE 32 ACELITY: COMPANY SNAPSHOT (2018)
FIGURE 33 ZIMMER BIOMET: COMPANY SNAPSHOT (2019)


More Publications